Top

Published in:

01-02-2010 | Brief Review

The underlying mechanisms for the ‘anti-HBc alone’ serological profile

Authors: R. A. A. Pondé, D. D. P. Cardoso, M. O. Ferro

Published in: Archives of Virology | Issue 2/2010

Abstract

The serological pattern, “anti-HBc alone”, characterized by the presence of antibodies against the core antigen of hepatitis B virus (anti-HBc) as the only marker of hepatitis B, is not rare in a diagnostic setting. Depending on the prevalence of HBV infection and the patient group investigated, 1–31% of positive anti-HBc results are isolated positive findings. Anti-HBc alone is frequently observed in intravenous drug addicts, HIV-infected individuals, patients who are coinfected with HBV and hepatitis C virus, and pregnant women. However, it is not clear how this profile should be interpreted. Several studies have shown that anti-HBc alone is not only compatible with acute and resolved HBV infection but also with chronic infection. The reasons for the lack of HBsAg and anti-HBs in anti-HBc-alone individuals are not clear, but several mechanisms and possibilities have been suggested that could explain this phenomenon, some of which are delineated in this article.

Milich DR, McLachlan A (1986) The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234:1398–1401CrossRefPubMed

Milich DR, Salberg M, Maruyama T (1995) The humoral immune response in acute and chronic hepatitis B virus infection. Springer Semin Immunopathol 17:140–166CrossRef

Jung M-C, Pape GR (2002) Immunology of hepatitis B infection. Lancet 2(1):43–50CrossRef

Laperche S, Guitton C, Smilovici W, Courouce AM (2001) Blood donors infected with the hepatitis B virus but persistently lacking antibodies to the hepatitis B core antigen. Vox Sang 80:90–94CrossRefPubMed

Busch MP (2004) Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Tranfus Clin Biol 11(1):26–32CrossRef

Alhababi F, Sallam T, Tong C (2003) The significance of ‘anti-HBc alone’ in the clinical virology laboratory. J Clin Virol 27:162–169CrossRefPubMed

Chan H (2002) Changing scene in hepatitis B serology interpretation. Hosp Med 63(1):16–19PubMed

Greub G, Frei PC (2001) Presence of low levels on anti-HBs antibody in so-called ‘anti-HBc alone’ subjects. Liver 21:380–383CrossRefPubMed

Grob JP, Jilg W, Bornhak H, Gerken G, Gerlich W, Gunther S, Hess G, Hudig H, Kitchen A, Margolis H, Michel G, Trepo C, Will H, Zanetti A, Mushahwar I (2000) Serological pattern ‘anti-HBc Alone’: report on a workshop. J Med Virol 62:450–455CrossRefPubMed

10.

Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H (2001) Hepatitis B virus markers in Anti-HBc only positive individuals. J Med Virol 64:312–319CrossRefPubMed

11.

Westh H, Hoffmann S, Christian E, Worm AM (1996) Hepatitis B core antibody screening in a high prevalence group: comparison of the three enzyme immunoassays using receiver operating characteristic analysis. J Virol Med 56(1):13–18CrossRef

12.

Weber B, Michl U, Muhlbacher A, Paggi G, Bossi V (1998) Evaluation of the new automated enzymun-test anti-HBc plus for the detection of hepatitis B virus core antibody. Intervirology 41(1):17–23CrossRefPubMed

13.

Weare JA, Robertson EF, Madsen G, Hu R, Decker RH (1991) Improvement in the specificity of assays for detection of antibody to hepatitis B core antigen. J Clin Microbiol 29(3):600–604PubMed

14.

Ural O, Findik D (2001) The response of isolated anti-HBc positive subjects to recombinant hepatitis B vaccine. J Infect 43(3):187–190CrossRefPubMed

15.

Lai C-L, Johnson Y, Yeoh E-K, Chang W-K, Lin H-J (1992) Significance of Isolated Anti-HBc Seropositivity by ELISA: implications and the role of radioimmunoassay. J Med Virol 36:180–183CrossRefPubMed

16.

Rodriguez JC, García DG, Teruel AB, Lorenz NF, Espeja AG (2005) Significado de la reactividad aislada anti-HBc como único marcador de infeccíon de la hepatitis B. Enferm Infecc Microbiol Clin 23(1):80–85CrossRef

17.

Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T (2000) Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31(2):488–495CrossRefPubMed

18.

Noborg U, Anki G, Horal P, Magnus L (2000) Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 32:249–252CrossRefPubMed

19.

Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Bréchot P (2001) Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 1(34):194–203CrossRef

20.

Zoulim F (2005) New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 42:302–308CrossRefPubMed

21.

Loriot M-A, Marcellin P, Walker F, Boyer N, Degott C, Randrianatoavina I, Benhamou JP, Erlinger S (1997) Persistence of hepatitis B Virus DNA in serum and Liver from patients with chronic hepatitis B after Loss of HBsAg. J Hepatol 27:251–258CrossRefPubMed

22.

Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, Chevalier P, Mandrand B, Trépo C (2001) High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 34:447–454CrossRefPubMed

23.

Zuckerman AJ, Zuckerman JN (2000) Current topics in hepatitis B. J Infect 41:130–136CrossRefPubMed

24.

Weber B (2004) The diagnostic and clinical impact of the genetic variability of the s gene of hepatitis B virus. J Lab Med 28(1):56–69

25.

Tonekaboni SS, Waters J, Jeffers S, Gehrke R, Ofenloch B, Horsch A, Hess G, Howard C, Karayiannis P (2000) Effect of variation in the common ‘a’ determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 60:113–121CrossRef

26.

Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillop G, Tanzi E, Zuckerman AJ, Thomas HC (1990) Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325–329CrossRefPubMed

27.

Karthiguesu V, Allison L, Fortuin M, Mendy M, Whittle H, Howard C (1994) A novel hepatitis B virus in the sera of immunized children. J Gen Virol 75:443–448CrossRef

28.

Jongerius J, Cuypers H, Van Oostendorp W, Lelie PN, Van der Poel CL, Leeuwen EF (1998) New hepatitis B virus mutant form in a blood donor that in undetectable in several hepatitis B surface antigen screening assays. Transfusion 38:56–59CrossRefPubMed

29.

Grethe S, Monazahian M, Bohme I, Thomsen R (1998) Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject. J Virol 9(72):7692–7696

30.

Weinberger KM, Bauer T, Bohm S, Jilg W (2000) High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 81:1165–1174PubMed

31.

Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R (1995) Fulminant reactivation of hepatitis B virus due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 345:1406–1407CrossRefPubMed

32.

Stuyver L, Locarnini S, Lok A, Richman D, Carman W, Dienstag J (2001) Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751–757CrossRefPubMed

33.

Torresi J (2002) The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25(2):97–106CrossRefPubMed

34.

Torresi J, Erneste-Silveira L, Civitico G, Walters T, Lewin S, Fyfe J, Locarnini S, Manns M, Trautwein C, Bock T (2002) Restoration of replication phenotype of lamivudine-resistant Hepatitis B mutants by compensatory changes in the fingers subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299(1):88–99CrossRefPubMed

35.

Wakil SM, Kazim SN, Khan LA (2002) Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol 68:311–318CrossRefPubMed

36.

Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F (1999) Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29:230–237CrossRefPubMed

37.

Xiong X, Yang H, Westland CE, Zou R, Gibbs CS (2000) In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 31:219–224CrossRefPubMed

38.

Krastev AZ (2006) The “return” of hepatitis B. W J Gastroenterol 12(44):7081–7086

39.

Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert Tf, Gut J-P, Stoll-Keller F, Schvoerer E (2009) Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naïve patients. W J Gastroenterol 15(6):753-755.

40.

Nagasaki F, Niitsuma H, Ueno Y, Imoue J, Kogure T, Fukushima K, Shimisegawa T (2007) The high incidence of the emergence of entecavir-resistant mutant among patients infected with Lamivudine-resistant hepatitis B virus. Tohoku J Exp Med 213:181–186CrossRefPubMed

41.

Angus P, Vaughan R, Yiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutations in the HBV polymerase. Gastroenterology 125:292–297CrossRefPubMed

42.

Sheldon J, Camino N, Rodes B (2005) Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenefovir. Antivir Ther 10:727–734PubMed

43.

Yang H, Westland CE, Delaney W (2002) Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatotlogy 36:464–473CrossRef

44.

Baumert TF, Blum HE (2005) Hepatitis B virus mutations: molecular biology and clinical relevance. Vir Rev 6:177–192

45.

Baumert TF, Thimme R, von Weizsacker F (2007) Pathogenesis of hepatitis B virus infection. W J Gastroenterol 13(1):82–90

46.

Kazim SN, Sarin SK, Sharme BC, Khan LA, Hasnain SE (2006) Characterization of naturally occurring and lamivudine-induced surface gene mutations of hepatitis B virus in patients with chronic hepatitis B in India. Intervirol 49:152–160CrossRef

47.

Sheldon J, Ròdes B, Zoulim F, Bartholomeusz A, Soriano V (2006) Mutations affecting the replication capacity of the hepatitis B virus. J Virol Hep 13:427–434CrossRef

48.

Bock C, Tillmann H, Manns M, Trautwein C (1999) The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology 30(2):517–525CrossRefPubMed

49.

Melegari M, Pier PS, Wands JR (1997) The small envelope protein is required for secretions of a naturally occurring Hepatitis B virus mutant with Pre-S1 deleted. J Virol 7(71):5449–5454

50.

Bock C, Tillman H, Maschek H, Manns M, Trautwein C (1997) A pre-S mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 113:1976–1982CrossRefPubMed

51.

Lee S-Y, Choi MS, Lee D, Lee H, Koh KC, Paik SW, Yoo BC (2005) Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J Korean Med Sci 20:433–437CrossRefPubMed

52.

Sengupta S, Rehman S, Durgapal H, Acharya S, Panda S (2007) Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol 79:220–228CrossRefPubMed

53.

Blackberg J, Kidd-Ljunggren K (2000) Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 33:992–997CrossRefPubMed

54.

Squadrito G, Orlando M, Pollicino T, Raffa G, Restuccia T, Cacciola I, Di Marco V, Picciotto A, Colucci G, Craxi A, Raimondo G (2002) Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 97(6):1518–1523CrossRefPubMed

55.

Otedo AE, McLigeyo SO, Okoth FA, Kayima JK (2003) Seroprevalence of hepatitis B and C in maintenance dialysis in a public hospital in a developing country. S Afr Med J 93(5):380–384PubMed

56.

De-Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH (2000) The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 95(12):3529–3536CrossRefPubMed

57.

Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, Kushiyama Y, Uchida Y, Ihihara S, Akagi S, Watanabe M, Kinoshita Y (1999) Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 58(3):201–207CrossRefPubMed

58.

Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160–170CrossRefPubMed

59.

Inigo R, Mariscal L, Bartolomé J, Castillo I, Navacerrada C, Movilla N, Pardo M, Carrero V (2003) Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection. J Med Virol 70:571–580CrossRef

60.

Weber B, Melchior W, Gehrke R, Doerr WH, Berger A, Rabenau H (2001) Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 64:312–319CrossRefPubMed

61.

Schuttler C, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S (2002) Suppression of hepatitis B virus enhancer 1 e 2 by hepatitis C virus core protein. J Hepatol 37(6):855–862CrossRefPubMed

62.

Lusida MI, Sakugawa H, Motroko N-F, Muluanto S, Handajani R, Boediwarsono, Setiawan PB, Nidom CA, Ohgimoto S and Hotta H (2003) Genotype and Subtype Analyses of Hepatitis B Vírus (HBV) and Possible Co-Infection of HBV and Hepatitis C Virus (HCV) or Hepatitis D Vírus (HDV) in Blood Donors, Patients with Chronic Liver Disease and Patients on Hemodialysis is Surabaya, Indonesia. Microbiol Immunol 47(12):969-975

63.

Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR (1993) The serology of chronic hepatitis B infection revisited. J Clin Invest 91:2586–2595CrossRefPubMed

64.

Joller-Jemelka HI, Wicki AN, Grob P (1994) Detection of HBs antigen in ‘anti-HBc alone’ positive sera. J Hepatol 21(2):269–272CrossRefPubMed

65.

Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujioe H, Tsutsumi T, Kimura S, Koike K (1998) Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 27(5):1377–1382CrossRefPubMed

66.

Greub G, Frei P (2001) Presence of low levels of anti-HBs antibody in so-called ‘anti-HBc alone’ subjects. Liver 21:380–383CrossRefPubMed

67.

Yamauchi K, Nakanishi T, Chiou S-S, Obata H (1998) Suppression of hepatitis B antibody synthesis by factor made by T cells from chronic hepatitis B carriers. Lancet 1:324–326

68.

Bocher WO, Herzog-Hauff S, Schlaak J, Meyer zum Buschenfeld K, Lohr HF (1999) Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 29(1):238–244CrossRefPubMed

69.

Milich DR, Leroux-Roels GG (2003) Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2(5):248–257CrossRefPubMed

70.

Desombere I, Willems A, Gijbels Y, Leroux-Roels G (2006) Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen. J Virol 80(7):3506–3514CrossRefPubMed

71.

Wang R-X, Boland G, Hattum J, de Gast GC (2004) Long term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol 10(2):260–263PubMed

72.

Bocher B, Herzog-Hauff S, Herr W, Heermann K, Gerken G, Meyer ZUMB, Lohr HF (1996) Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 105(1):52–58CrossRefPubMed

73.

Bauer T, Jilg W (2006) Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24(5):572–577PubMed

74.

Greub G, Zysset F, Genton B, Spertini F, Frei PC (2001) Absence of anti-hepatitis B surface antibody after vaccination does not necessarily mean absence of immune response. Med Microbiol Immunol (Berl) 189(3):165–168CrossRef

75.

Heijtink RA, Schneeberger PM, Postma B, Crombach W (2002) Anti-HBs levels after hepatitis B immunization depend on test reagents: routinely determined 10 and 100 IU/L seroprotection levels unreliable. Vaccine 20(23/24):2899–2905CrossRefPubMed

76.

Hou J, Lui Z, Gu F (2005) Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2(1):50–57PubMed

77.

Kao JH, Chen DS (2002) Global control of hepatitis B virus infection. Lancet 2:395–403CrossRef

78.

Allain J-P (2004) Occult hepatitis B virus infection: implications in transfusion. Vox Sang 86:83–91CrossRefPubMed

79.

Zervou EK, Dalekos GN, Boumba DS, Tsianos EV (2001) Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-years prospective study in Northwestern Greece. Transfusion 41:652–658CrossRefPubMed

80.

Liu C-J, Chen D-S, Chen P-J (2006) Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection ant the role of NAT. J Clin Virol 36:S33–S44CrossRefPubMed

81.

Wang JT, Wang TH, Lee C-Z, Chen P-J, Wang T-H, Chen D-S (2002) Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 42:1592–1597CrossRefPubMed

82.

Arraes LC, Ximenez R, Andrieu J-M, Lu-W, Barreto S, Pereira LM, Castelo A (2003) The biological meaning of anti-HBc positive in blood donors: Relation to HBV-DNA and to other serological markers. Rev Inst Med Trop S Paulo 45(3):137–140

83.

García-Montalvo B, Farfán-Ale J, Acosta-Viana K, Puerto-Manzano F (2005) Hepatitis B virus DNA in blood donors with anti-HBc as a possible indicator of active hepatitis B virus infection in Yucatan, México. Transfus Med 15(5):371–378CrossRefPubMed

84.

Ramia S, Ramlawi F, Kanaan M, Klayme S, Naman R (2005) Frequency and significance of antibodies against hepatitis B core (anti-HBc) antigen as the only serological marker for hepatitis B infection in Lebanese blood donors. Epidemiol Infect 133(4):695–699CrossRefPubMed

85.

Behzad-Behbahani A, Mafi-Nejad A, Tabei SZ, Lankarani KB, Torab A, Moaddeb A (2006) Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res 123(1):37–42PubMed

86.

Banerjee A, Chandra P, Datta S, Biswas A, Bhattacharya P, Chakraborty S, Chakrabarti S, Bhattacharya S, Chakrabarty R (2007) Frequency and significance of hepatitis B virus surface gene variant circulating among ‘anti-HBc only’ individuals in Eastern India. J Clin Virol 40:312–317CrossRefPubMed

87.

Kleinman S, Kuhns M, Todd D, Glynn S, McManara A, DiMarco A, Busch M (2003) Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 43:696–704CrossRefPubMed

88.

Sciariada L, Grando D, Lochato A, Magni E (1991) Immune response to hepatitis B vaccine in persons with “anti-HBcAlone”. In: Hollinger FB, Lemon SM, Margolis HS (eds) Proceedings of the 1990 international symposium on viral hepatitis and liver disease: viral hepatitis and liver disease. Willians & Wilkins, pp 782–784

89.

Sunbul M, Leblebicioglu H, Esen S, Eroglu C, Barut S (2000) Response to hepatitis B vaccine in HBsAg/Anti-HBs negative and anti-HBc positive subjects. Scan J Infect Dis 32:315–316CrossRef

Title: The underlying mechanisms for the ‘anti-HBc alone’ serological profile
Authors: R. A. A. Pondé
D. D. P. Cardoso
M. O. Ferro
Publication date: 01-02-2010
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 2/2010
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-009-0559-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Structure and genome organization of the large RNA of iris yellow spot virus (genus Tospovirus, family Bunyaviridae)

Partial genetic characterization of viruses isolated from pox-like infection in cattle and buffaloes: evidence of buffalo pox virus circulation in Indian cows

Secular trend of genome types of respiratory adenovirus type 3 during 1983–2005: a study from Taiwan

Genetic diversity of the S10 RNA segment of field and vaccine strains of bluetongue virus from the P. R. China

Implementation of real-time RT-PCR for detection of human metapneumovirus and its comparison with enzyme immunoassay

Complete genome sequence of a tobacco isolate of the tobacco vein banding mosaic virus strain prevailing in China

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials